Tumor Biology

, Volume 36, Issue 6, pp 4075–4078 | Cite as

New approaches for cancer immunotherapy

Review

Abstract

Immunotherapy is a promising field that offers alternative methods for treatment of cancer. The current strategy consists of cancer vaccines, monoclonal antibodies, and cellular therapies. Cancer vaccines aim to eradicate cancer cells via immune system. Thus, they may attack these cells derived from any type of cancer, besides their role in preventing cancer. Lymphocytes and dendritic cells are often used in cellular therapy. In addition, monoclonal antibodies are designed to target specific antigens found in cancer cells. Currently, at least 12 clinically approved monoclonal antibodies are being used and many cancer vaccines are being developed with ongoing phase studies for cancer therapy. Relevant studies are focused on glioma and several other cancer types. Correspondingly, the combination of effective methods may enhance the efficacy of immunotherapy. It is thought that particularly immune checkpoint inhibitors will play a crucial role in immunotherapeutic approaches.

Keywords

Cancer immunotherapy Monoclonal antibody Cancer vaccine Glioma 

References

  1. 1.
    Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–80.Google Scholar
  2. 2.
    Çağrı Ş, Halit C, Kenan İ. Kanser İmmün Terapi ve MonoklonalAntikorlar. Fırat Üniv Sağlık Bilimleri Tıp Derg. 2013;27(2):105–10.Google Scholar
  3. 3.
    Old LJ, Scott AM, Wolchok JD. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.CrossRefPubMedGoogle Scholar
  4. 4.
    Andrea S, Hans S, Mary P. Specificity in cancer immunotherapy. Semin Immunol. 2008;20(5):276–85.CrossRefGoogle Scholar
  5. 5.
    Rini B. Future approaches in immunotherapy. Semin Immunol. 2014;5:30–40.Google Scholar
  6. 6.
    June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117(6):1466–76.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013;1:12.Google Scholar
  8. 8.
    Akiko K, Akira I, Chie O, Ken Y, Koichi M, Masaru K, et al. Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. Immunol Lett. 2014;159:15–22.CrossRefGoogle Scholar
  9. 9.
    Hiroaki W, Jianfang N, Samuel D. Immunovirotherapy for glioblastoma. Cell Cycle. 2014;13(2):175–6.CrossRefGoogle Scholar
  10. 10.
    Ming X, Ping Z, Wei H, Yu Y, Zhebao W. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells. J Neuro-Oncol. 2014;116:497–504.CrossRefGoogle Scholar
  11. 11.
    Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, Lesniak MS. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther. 2014;21:38–44.Google Scholar
  12. 12.
    Anna D, Edward V, Emma S, Sofia E. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors. Int J Cancer. 2014;134:2748–53.CrossRefGoogle Scholar
  13. 13.
    Bart T, Brown CE, Emanuela B, Katherine W, Prakash S, Sadhak S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncology. 2014;16(10):1304–12.CrossRefGoogle Scholar
  14. 14.
    Alexander S, Fabian W, Isabel T, Michael W. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro-Oncology. 2014;16(3):382–91.CrossRefGoogle Scholar
  15. 15.
    Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.Google Scholar
  16. 16.
    Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword. Oncotarget. 2014;5(16):6558–72.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ayfer Karlitepe
    • 1
  • Ozgun Ozalp
    • 2
  • Cigir Biray Avci
    • 2
  1. 1.Department of Medical Biochemistry, Medical SchoolEge UniversityIzmirTurkey
  2. 2.Department of Medical Biology, Medical SchoolEge UniversityIzmirTurkey

Personalised recommendations